Aptinyx (APTX) Is A Stock That Leerink Partners Seems to be Very Interested In

July 16, 2018 - By Victoria Pittman

Why Has Leerink Partners Given Aptinyx (APTX) a $35.0 Price Target

Analysts at Leerink Partners started coverage on shares of Aptinyx (APTX) in a research report released on 16 July. The company set Outperform rating on the $690.02 million market cap company.

The stock decreased 2.23% or $0.47 during the last trading session, reaching $20.6. About 72,006 shares traded. Aptinyx Inc. (APTX) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company has market cap of $690.02 million. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. It currently has negative earnings. The firm has a collaboration agreement with Allergan plc.

More notable recent Aptinyx Inc. (NASDAQ:APTX) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More” on July 14, 2018, also Streetinsider.com with their article: “Aptinyx (APTX) IPO Opens 9% Higher” published on June 21, 2018, 247Wallst.com published: “IPO News This Week: A Record 12 IPOs Coming to Market” on June 24, 2018. More interesting news about Aptinyx Inc. (NASDAQ:APTX) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” published on June 29, 2018 as well as Streetinsider.com‘s news article titled: “BMO Capital Starts Aptinyx (APTX) at Outperform” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.